ジェイファーマ株式会社

Tokyo, JP · 6 known investors

J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.

BiotechDigital HealthHealthtechMedical Devices